Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atezolizumab + Cisplatin
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Atezolizumab + cisplatin is a combination therapy used in cancer treatment, particularly for lung cancer. This combination pairs atezolizumab, an immune checkpoint inhibitor, with cisplatin, a platinum-based chemotherapy agent. When combined, these medications provide a dual approach to fighting cancer - direct cytotoxic effects from cisplatin and immune system activation from atezolizumab.
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on Atezolizumab + Cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atezolizumab + Cisplatin.